[go: up one dir, main page]

EE04817B1 - Kudede regeneratsiooni modulaatorid - Google Patents

Kudede regeneratsiooni modulaatorid

Info

Publication number
EE04817B1
EE04817B1 EE9800409A EE9800409A EE04817B1 EE 04817 B1 EE04817 B1 EE 04817B1 EE 9800409 A EE9800409 A EE 9800409A EE 9800409 A EE9800409 A EE 9800409A EE 04817 B1 EE04817 B1 EE 04817B1
Authority
EE
Estonia
Prior art keywords
modulators
tissue regeneration
purified
new
nucleic acid
Prior art date
Application number
EE9800409A
Other languages
English (en)
Estonian (et)
Other versions
EE9800409A (et
Inventor
Sanicola-Nadel Michele
V. Bonventre Joseph
A. Hession Catherine
Ichimura Takaharu
Wei Henry
L. Cate Richard
Original Assignee
Biogen, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26690881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE04817(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen, Incorporated filed Critical Biogen, Incorporated
Publication of EE9800409A publication Critical patent/EE9800409A/xx
Publication of EE04817B1 publication Critical patent/EE04817B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Optics & Photonics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Electrotherapy Devices (AREA)
EE9800409A 1996-05-24 1997-05-23 Kudede regeneratsiooni modulaatorid EE04817B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1822896P 1996-05-24 1996-05-24
US2344296P 1996-08-23 1996-08-23
PCT/US1997/009303 WO1997044460A1 (en) 1996-05-24 1997-05-23 Modulators of tissue regeneration

Publications (2)

Publication Number Publication Date
EE9800409A EE9800409A (et) 1999-06-15
EE04817B1 true EE04817B1 (et) 2007-04-16

Family

ID=26690881

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800409A EE04817B1 (et) 1996-05-24 1997-05-23 Kudede regeneratsiooni modulaatorid

Country Status (26)

Country Link
US (4) US6664385B1 (xx)
EP (2) EP1655367A1 (xx)
JP (3) JP4602482B2 (xx)
CN (1) CN1147584C (xx)
AT (1) ATE318903T1 (xx)
AU (1) AU712289B2 (xx)
BG (1) BG64678B1 (xx)
BR (1) BR9709115A (xx)
CA (1) CA2257851C (xx)
CZ (1) CZ295936B6 (xx)
DE (1) DE69735364T3 (xx)
DK (1) DK0907735T5 (xx)
EA (1) EA004402B1 (xx)
EE (1) EE04817B1 (xx)
ES (1) ES2258793T5 (xx)
HU (1) HU226205B1 (xx)
IL (1) IL127162A (xx)
IS (1) IS2636B (xx)
NO (2) NO327597B1 (xx)
NZ (1) NZ336467A (xx)
PL (1) PL188826B1 (xx)
PT (1) PT907735E (xx)
SI (1) SI0907735T2 (xx)
SK (1) SK285461B6 (xx)
TR (1) TR199802421T2 (xx)
WO (1) WO1997044460A1 (xx)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044460A1 (en) * 1996-05-24 1997-11-27 Biogen, Inc. Modulators of tissue regeneration
CA2290783A1 (en) * 1997-05-23 1998-11-26 Biogen, Inc. Modulators of tissue regeneration
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
ES2374534T3 (es) 1998-03-20 2012-02-17 Commonwealth Scientific And Industrial Research Organisation Control de la expresión de genes.
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
EP1160321A1 (en) * 2000-05-31 2001-12-05 Sanofi-Synthelabo Kidney Injury Novel Gene-1: Isolation and therapeutic applications
DE60137934D1 (de) * 2000-06-16 2009-04-23 Biogen Idec Inc Renale regulatorische elemente und deren verwendung
US6812002B2 (en) * 2000-08-30 2004-11-02 Pfizer Inc. Osteoactivin protein and nucleic acids encoding the same, compositions and methods of stimulating bone differentiation
JP4527394B2 (ja) * 2001-06-01 2010-08-18 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｋｉｍ−１の分断を阻害するための分子および方法
NZ530451A (en) 2001-06-29 2008-04-30 Univ Leland Stanford Junior TIM gene sequences and their use in immunological disorders and cancer
US8709412B2 (en) 2001-06-29 2014-04-29 The Board Of Trustees Of The Leland Stanford Junior University Modulation of TIM receptor activity in combination with cytoreductive therapy
WO2003080856A2 (en) * 2002-03-19 2003-10-02 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP2025345A1 (en) * 2002-12-30 2009-02-18 Biogen Idec MA Inc. KIM-1 antagonists and use to modulate immune system
AU2004224390A1 (en) 2003-03-19 2004-10-07 Abgenix, Inc. Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof
EP1616184B2 (en) * 2003-03-27 2018-05-30 Children's Hospital Medical Center A method and kit for detecting the early onset of renal tubular cell injury
AU2005240190C1 (en) 2004-05-06 2012-01-19 Children's Hospital Medical Center NGAL for reduction and amelioration of ischemic and nephrotoxic injuries
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
RU2283666C9 (ru) * 2004-05-14 2007-03-10 Бизяев Алексей Вячеславович Средство для активации восстановления структуры и функции поврежденных тканей и органов
US20060003345A1 (en) * 2004-06-30 2006-01-05 Pfizer Inc RNA bioassay
ES2818028T3 (es) * 2004-12-20 2021-04-09 Antibodyshop As Determinación de lipocalina asociada a gelatinasa de neutrófilos (NGAL) como marcador diagnóstico para trastornos renales
NZ562045A (en) 2005-03-02 2010-12-24 Biogen Idec Inc Kim-1 antibodies for treatment of TH2-mediated conditions
WO2007059082A1 (en) 2005-11-10 2007-05-24 Curagen Corporation Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
EP2035835B1 (en) 2006-05-30 2011-12-28 Antibodyshop A/S Methods for rapid assessment of severity of a trauma
JP2010500535A (ja) * 2006-08-07 2010-01-07 アンチボディショップ・アクティーゼルスカブ 重大な腎損傷を除外するための診断検査
EP2137538B1 (en) * 2007-03-21 2014-04-09 Bioporto Diagnostics A/s Diagnostic test for renal injury
US8846036B2 (en) 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
US20090297479A1 (en) * 2008-03-28 2009-12-03 Kiyoshi Ariizumi Dc-hil conjugates for treatment of t-cell disorders
WO2010025424A1 (en) * 2008-08-28 2010-03-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5947544B2 (ja) * 2008-08-29 2016-07-06 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後のための方法および組成物
AU2009308375B2 (en) * 2008-10-21 2015-06-25 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3974836A1 (en) 2008-10-21 2022-03-30 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
BRPI0922021A2 (pt) 2008-11-10 2019-09-24 Astute Medical Inc método para avaliar a condição renal em um indivíduo, e, uso de um ou mais marcadores de lesão renal
CN104034901A (zh) * 2008-11-22 2014-09-10 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
CA2748852C (en) * 2009-01-28 2019-05-28 Industrial Technology Research Institute Biomarkers associated with nephropathy
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ598035A (en) 2009-08-07 2014-06-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US8871459B2 (en) 2009-08-07 2014-10-28 Astute Medical, Inc. Method for evaluating renal status by determining beta-2-glycoprotein 1
EP2496942B1 (en) 2009-11-07 2017-03-22 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102725636B (zh) 2009-12-20 2015-04-01 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
NZ700695A (en) 2010-02-05 2016-05-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5998057B2 (ja) 2010-02-26 2016-11-30 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断と予後のための方法と組成物
WO2011162819A1 (en) 2010-06-23 2011-12-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ES2667066T3 (es) 2010-05-24 2018-05-09 The Trustees Of Columbia University In The City Of New York Proteínas NGAL mutantes y usos de las mismas
WO2011162821A1 (en) 2010-06-23 2011-12-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
BR112013020312B1 (pt) * 2011-02-09 2021-03-23 Synbiotics Ab Composições simbióticas para restauração e reconstituição da microbiota intestinal
US10935548B2 (en) 2011-12-08 2021-03-02 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
EP2925337B1 (en) 2012-11-21 2019-07-03 The Trustees of Columbia University in the City of New York Mutant ngal proteins and uses thereof
ES2926197T3 (es) 2013-01-17 2022-10-24 Astute Medical Inc Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
US10420337B2 (en) 2013-03-15 2019-09-24 Lifeline Scientific, Inc. Transporter with a glucose sensor for determining viability of an organ or tissue
WO2015134671A1 (en) 2014-03-04 2015-09-11 Targeson, Inc. Molecular imaging contrast agents and uses thereof
EP3465201A4 (en) 2016-06-06 2020-08-26 Astute Medical, Inc. MANAGEMENT OF ACUTE KIDNEY DAMAGE USING INSULINOMIMETIC GROWTH FACTOR BINDING PROTEIN 7 AND TISSUE METALLOPROTEINASE 2 INHIBITOR

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2003A (en) * 1841-03-12 Improvement in horizontal windivhlls
US5019368A (en) * 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
WO1993022332A2 (en) * 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
CA2166313A1 (en) * 1994-02-14 1995-08-17 John N. Simons Non-a, non-b, non-c, non-d, non-e hepatitis reagents and methods for their use
US5622861A (en) * 1994-08-05 1997-04-22 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA encoding hepatitis A virus receptor
CA2196892A1 (en) * 1994-08-18 1996-02-29 The Trustees Of Columbia University Unique associated kaposi's sarcoma virus sequences and uses thereof
US6069230A (en) * 1994-11-10 2000-05-30 Promega Corporation High level expression and facile purification of proteins, peptides and conjugates for immunization, purification and detection applications
US6066322A (en) * 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
WO1997044460A1 (en) * 1996-05-24 1997-11-27 Biogen, Inc. Modulators of tissue regeneration
DE60137934D1 (de) * 2000-06-16 2009-04-23 Biogen Idec Inc Renale regulatorische elemente und deren verwendung
JP4527394B2 (ja) * 2001-06-01 2010-08-18 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｋｉｍ−１の分断を阻害するための分子および方法
NZ530451A (en) * 2001-06-29 2008-04-30 Univ Leland Stanford Junior TIM gene sequences and their use in immunological disorders and cancer
US7838220B2 (en) * 2001-06-29 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes associated with immune disease
US7215871B2 (en) * 2001-07-27 2007-05-08 Thomson Licensing Changing a playback speed for video presentation recorded in a field structure format
US7687454B2 (en) * 2001-12-03 2010-03-30 The University Of British Columbia Effectors of innate immunity determination
EP3020413A1 (en) * 2002-01-30 2016-05-18 The Brigham and Women's Hospital, Inc. Compositions and methods related to TIM-3, a TH1-specific cell surface molecule
WO2003080856A2 (en) * 2002-03-19 2003-10-02 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP2025345A1 (en) * 2002-12-30 2009-02-18 Biogen Idec MA Inc. KIM-1 antagonists and use to modulate immune system
TW200539890A (en) * 2004-03-12 2005-12-16 Brigham & Womens Hospital Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
JP2007530560A (ja) * 2004-03-24 2007-11-01 テロス ファーマシューティカルズ， インコーポレイテッド ワクチンに対する免疫応答を向上させるためのアジュバントおよび使用方法

Also Published As

Publication number Publication date
CA2257851A1 (en) 1997-11-27
CN1223685A (zh) 1999-07-21
EP0907735B2 (en) 2009-10-07
IL127162A (en) 2007-07-24
HUP9902770A3 (en) 2001-09-28
JP2001505761A (ja) 2001-05-08
NZ336467A (en) 2000-10-27
TR199802421T2 (xx) 1999-02-22
SK285461B6 (sk) 2007-02-01
HUP9902770A2 (hu) 1999-12-28
EP0907735B1 (en) 2006-03-01
ES2258793T3 (es) 2006-09-01
US20070141590A1 (en) 2007-06-21
DK0907735T3 (da) 2006-06-26
HK1021746A1 (en) 2000-06-30
EP0907735B9 (en) 2010-05-19
BG64678B1 (bg) 2005-11-30
EA199801044A1 (ru) 1999-04-29
AU3567697A (en) 1997-12-09
ATE318903T1 (de) 2006-03-15
SI0907735T1 (sl) 2006-08-31
US20050089868A1 (en) 2005-04-28
EP0907735A1 (en) 1999-04-14
BG102967A (bg) 2000-05-31
IL127162A0 (en) 1999-09-22
US6664385B1 (en) 2003-12-16
EE9800409A (et) 1999-06-15
JP4316640B2 (ja) 2009-08-19
DK0907735T4 (da) 2009-12-21
PL330313A1 (en) 1999-05-10
NO985427D0 (no) 1998-11-20
SK160998A3 (en) 1999-07-12
NO20090945L (no) 1999-01-25
JP2008067701A (ja) 2008-03-27
CN1147584C (zh) 2004-04-28
IS4902A (is) 1998-11-20
CA2257851C (en) 2011-11-15
NO327597B1 (no) 2009-08-31
EP1655367A1 (en) 2006-05-10
CZ295936B6 (cs) 2005-12-14
PL188826B1 (pl) 2005-04-29
DE69735364D1 (de) 2006-04-27
CZ381398A3 (cs) 1999-05-12
JP2009039111A (ja) 2009-02-26
SI0907735T2 (sl) 2010-01-29
HU226205B1 (en) 2008-06-30
WO1997044460A1 (en) 1997-11-27
NO985427L (no) 1999-01-25
EA004402B1 (ru) 2004-04-29
US20060286031A1 (en) 2006-12-21
PT907735E (pt) 2006-06-30
ES2258793T5 (es) 2010-01-25
DE69735364T3 (de) 2010-05-06
AU712289B2 (en) 1999-11-04
DE69735364T2 (de) 2006-11-30
DK0907735T5 (da) 2010-06-14
IS2636B (is) 2010-06-15
BR9709115A (pt) 1999-08-03
JP4602482B2 (ja) 2010-12-22

Similar Documents

Publication Publication Date Title
EE9800409A (et) Kudede regeneratsiooni modulaatorid
ATE328896T1 (de) Faktor viii vom schwein und hybriden
FI972333L (fi) Entsymaattiset DNA-molekyylit
DE69524365D1 (de) Verfahren zur Isolierung und Reinigung von 2'-Deoxy-2',2'-difluornucleosiden
DE69636147D1 (de) Verfahren zur herstellung von phosphorothioat-oligomeren
DE69527803D1 (de) Aufgereinigte dna-polymerase von thermococcus barossii
WO1997023611A3 (de) Nukleinsäuresequenzen von genen der high mobility group proteine sowie verwendungen derselben
DK0920501T3 (da) Neuritin, et neurogen
FI962087L (fi) Olefiinien polymerointiin tarkoitettu stereospesifinen katalyyttisysteemi ja monivaiheiset polymerointiprosessit, joissa tätä systeemiä käytetään
ZA9710163B (en) Novel carboxylesterase nucleic acid molecules, proteins and uses thereof.
DE69728897D1 (de) Saeugetierchemokine
DE69730364D1 (de) Verfahren zur Reinigung von 2,6-Dimethylnaphthol und dessen Verwendung bei der Herstellung von 2,6-Naphtholdicarbonsäure
MX9806041A (es) Proteina purificada sr-p70.
DE59506870D1 (de) Verfahren zur Herstellung von Polyamiden auf Basis von alpha,omega-Dinitrilen
CO4480058A1 (es) Genes codificantes y procedimiento de expresion de una nueva enzima: ftalil amidasa
BR9712767A (pt) Expressão especìfica para tecido de proteìna de retinoblastoma
DE69708481D1 (de) Verfahren zur Herstellung von sehr reinen 2,6-Dimethylnaphthalin
DE59702263D1 (de) Reinigung von p.p-Bisphenolat-Lösungen
BR9710992A (pt) Derivados anticovulsivos úteis no tratamento de psorìase
DE3777359D1 (de) Aminosaeuresequenz des menschlichen alpha 2-plasmininhibitors und cdns sowie diese aminosaeuresequenz codierende genomische dns.
DE69607582D1 (de) Verfahren zur Herstellung und Reinigung von 1,1,1-Tris(4-hydroxyphenyl)ethan
MA23574A1 (fr) Nouveaux derives alcanes 1,1-bis (heteroazolyl) et leur utilisation comme agents neuro-inhibiteurs
DE69709021D1 (de) Reinigung von Pentafluorethan
DE59708626D1 (de) Verfahren zur herstellung von 4,5,6-trichlor- und 2,4,5,6-tetrachlorpyrimidin
DE59609353D1 (de) Mittel zur subkutanen Verabreichung von Protein C

Legal Events

Date Code Title Description
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231